News · 26 weeks135-46%
2025-12-282026-06-21
Mix6990d
- Other43(62%)
- Insider14(20%)
- SEC Filings6(9%)
- Earnings3(4%)
- Analyst2(3%)
- Dividends1(1%)
Latest news
25 items- PRAllergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patientsCanada is the first country to approve a new botulinum neurotoxin serotype for aesthetic use Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved for the temporary improvement in the appearance of glabellar linesBoey® offers a differentiated treatment option for many people who are curious about facial injectablesResults may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeksBOTOX Cosmetic® (onabotulinumtoxinA) is the only neurotoxin clinically tested for use following treatment with Boey®IRVINE, Calif., June 23, 2026 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE:AB
- PRAbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus InfectionMAVIRET® (glecaprevir/pibrentasvir) is now approved in the European Union for the treatment of acute hepatitis C virus (HCV) infection with compensated liver disease (with or without cirrhosis) in adults and children aged 3 years and older.The approval gives clinicians an option to initiate treatment as soon as acute infection is confirmed, aiming to reduce delays in care and lower the risk of liver disease progression, cirrhosis and liver cancer.As the only treatment approved in the EU for both acute and chronic HCV infection, MAVIRET may help streamline care pathways and support broader efforts to advance HCV elimination goals.NORTH CHICAGO, Ill., June 23, 2026 /PRNewswire/ -- AbbVie (NYSE
- PRAbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque PsoriasisSKYRIZI® (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasis1Approval was based on the pivotal Phase 3 OptIMMize-1 and OptIMMize-2 trials which include a new 55 mg pre-filled syringe to support weight-based dosing for patients weighing less than 40 kg1Nearly a third of people living with psoriasis develop symptoms before the age of 18, often getting lesions on highly visible areas2,3NORTH CHICAGO, Ill., June 23, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the European Commission (EC) has approved SKYRIZI® (risankizumab) for the treatment of children and adolescents six years of age and older w
- SECAbbVie Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - AbbVie Inc. (0001551152) (Filer)
- PRAbbVie to Acquire Apogee Therapeutics, Deepening Immunology PortfolioProposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseasesApogee's lead asset, zumilokibart (APG777), is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitisApogee's pipeline also includes combinations of its novel antibodies; APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), is being developed in asthmaApogee shareholders to receive $135.11 per share in cash, for a total equity value of approximately $10.9 billionAbbVie
- PRAbbVie Declares Quarterly DividendNORTH CHICAGO, Ill., June 18, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.73 per share. The cash dividend is payable August 14, 2026, to stockholders of record at the close of business on July 15, 2026.Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges
- PRFresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma FirepowerIssued on behalf of Conexeu Sciences Inc.A clutch of new directors with Fortune 500 finance, M&A, and aesthetics pedigrees signals that the newly public tissue-regeneration company is building for commercialization — in one of medicine's most consequential frontiers.RENO, Nev., June 16, 2026 /CNW/ -- American News Group News Commentary — There is a well-worn pattern in the life sciences: a company spends years on the science, goes public, and then — in the critical window right after listing — races to assemble the kind of leadership bench that can turn a promising platform into a real business. The names a young company recruits in that window say a great deal about its ambitions. On June 1
- PRAllergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck AppearanceSKINVIVE by JUVÉDERM® is now the first and only hyaluronic acid injectable approved to reduce horizontal neck lines caused by "tech-neck.1"This is the second FDA-approved indication for SKINVIVE by JUVÉDERM®, which has been approved since 2023 to improve skin smoothness of the cheeks in adults.1IRVINE, Calif., June 16, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the U.S. Food and Drug Administration (FDA) approval of SKINVIVE by JUVÉDERM® to reduce neck lines for the improvement of neck appearance in adults over the age of 21.1 With this approval, SKINVIVE by JUVÉDERM® is the first and only hyaluronic acid (HA) injectable indicated to reduce the a
- FDAFDA Approval for SKYRIZI issued to ABBVIE INCSubmission status for ABBVIE INC's drug SKYRIZI (SUPPL-44) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/12/2026. Application Category: BLA, Application Number: 761105, Application Classification:
- FDAFDA Approval for SKYRIZI issued to ABBVIE INCSubmission status for ABBVIE INC's drug SKYRIZI (SUPPL-15) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/12/2026. Application Category: BLA, Application Number: 761262, Application Classification:
- PRAllergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in AestheticsReport says that younger adult consumers say satisfaction with their appearance impacts their mental (62%) and physical (53%) well-being.1IRVINE, Calif., June 10, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, today announced the release of What Consumers Really Want, the latest installment in The Aesthetics Evolution series. On the heels of The Hyaluronic Injectable Fillers Report, this report profiles today's aesthetics consumers, how their views on aesthetics are shaped and shifting, and what they expect from a personalized, end-to-end aesthetic experience. "Aesthetics is no longer transactional, it's transformational," said Nicole Mowad-Nassa
- PRAbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026Data being presented, including six oral presentations, reinforce AbbVie's leadership and commitment to ongoing research to improve outcomes for people living with blood cancers NORTH CHICAGO, Ill., June 8, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced it will share new data at the European Hematology Association (EHA) 2026 Congress and will showcase clinical advancements from research programs across multiple blood cancers, including multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and amyloidosis (AL). Featured data from AbbVie's blood cancer portfolio and pipeline include 21 o
- PRAbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceNORTH CHICAGO, Ill., June 2, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026. Management will participate in a fireside chat at 9:40 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key th
- SECSEC Form SD filed by AbbVie Inc.SD - AbbVie Inc. (0001551152) (Filer)
- PRAbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic LeukemiaAddition of VENCLYXTO plus acalabrutinib, with or without obinutuzumab, and VENCLYXTO plus ibrutinib supported by data from Phase 3 AMPLIFY trial, Phase 3 GLOW trial and Phase 2 CAPTIVATE trialFixed-duration VENCLYXTO-based combination regimens provide patients with additional CLL treatment options that may offer the potential for treatment-free intervals NORTH CHICAGO, Ill., May 29, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the European Commission (EC) has authorized an expanded label for VENCLYXTO® (venetoclax) to include use in combination with acalabrutinib (with or without obinutuzumab) and use in combination with ibrutinib for the treatment of adult patients with pre
- FDAFDA Approval for DECNUPAZ issued to ABBVIE INCSubmission status for ABBVIE INC's drug DECNUPAZ (ORIG-1) with active ingredient PIVEKIMAB SUNIRINE-PVZY has changed to 'Approval' on 05/27/2026. Application Category: BLA, Application Number: 761460, Application Classification:
- PRU.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options- DECNUPAZ is the first and only antibody-drug conjugate (ADC) approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) that is initiated in an outpatient setting- DECNUPAZ marks AbbVie's first ADC approved for blood cancerNORTH CHICAGO, Ill., May 27, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved DECNUPAZTM (pivekimab sunirine-pvzy) for the treatment of adult patients with BPDCN, an ultra-rare and aggressive hematologic malignancy with limited treatment options. The approval is supported by data from the Phase 1/2 CADENZA trial, a global study evaluating the safety and efficacy of DECNUPAZ for BPDCN. "For patien
- SECSEC Form 144 filed by AbbVie Inc.144 - AbbVie Inc. (0001551152) (Subject)
- PRAbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C InfectionThe positive opinion is supported by data from the Phase 3 M20-350 study evaluating the safety and efficacy of MAVIRET® in adults with acute hepatitis C virus (HCV) infection.MAVIRET is a direct-acting antiviral (DAA) treatment currently approved in the European Union for chronic HCV infection in adults and children aged 3 years and older.Acute HCV infection is often asymptomatic, highlighting the importance of early diagnosis and treatment to help reduce transmission, long-term liver-related complications, and support HCV elimination efforts.NORTH CHICAGO, Ill., May 22, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Prod
- PRAbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline- Data from novel Top1i ADC and T-cell engager platforms highlight potential within solid tumors and blood cancers, including oral presentations in prostate cancer, small cell lung cancer, platinum-resistant ovarian cancer and multiple myeloma - NORTH CHICAGO, Ill., May 21, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that it will present new data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago demonstrating the depth and breadth of its oncology pipeline. The data will be shared through multiple oral presentations and posters spanning solid tumors and blood cancer indications. Collectively, these presentations highlight AbbVie's continued focus
- PRAllergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in AdultsBoey® has received a positive opinion from the CHMP for 30 EU & EEA markets If approved, Boey® has the potential to be the first and only botulinum neurotoxin serotype E that adult patients can try for the temporary improvement of Glabellar LinesPositive opinion is supported by data from two pivotal Phase 3 trials, which demonstrated rapid results as early as 8 hours and duration of 2-3 weeks2NORTH CHICAGO, Ill., May 21, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV) and global leader in medical aesthetics, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending appro
- PRNext-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market OpportunitiesAUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (T2DM) rank among the most urgent and costly healthcare problems facing the world today, contributing to surging rates of cardiovascular disease, fatty liver disease, kidney complications and ballooning healthcare expenses. What once represented a specialized class of diabetes treatments has grown into one of the most consequential therapeutic categories in modern medicine, with GLP-1 receptor agonists now fundamentally restructuring how obesity, metabolic disease and potentially even neurodegeneration are treated. Operating in this environment is SureNano Science Ltd. (CSE:S
- PRCNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense ResearchAUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Among the most guarded structures in human biology, the brain is also one of the hardest to treat. The blood-brain barrier (BBB), a specialized biological membrane, shields neural tissue from foreign substances, including most therapeutic agents. As cases of Alzheimer's disease climb worldwide and governments sharpen their focus on biodefense, the absence of efficient pathways for delivering drugs to the brain is fast becoming one of medicine's most pressing unresolved problems. Companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile) are responding to this challenge with next-generation delivery pla
- SECAbbVie Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - AbbVie Inc. (0001551152) (Filer)
- INSIDERDirector Falk Thomas J was granted 1,118 shares, increasing direct ownership by 93% to 2,321 units (SEC Form 4)4 - AbbVie Inc. (0001551152) (Issuer)
ABBV FAQ
7 questionsWhat does AbbVie Inc. do?
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus...Where does ABBV stock trade?
AbbVie Inc. (ABBV) is listed on NYSE.What sector and industry is ABBV in?
AbbVie Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did AbbVie Inc. go public?
AbbVie Inc. (ABBV) completed its IPO in 2012.What are analysts saying about ABBV?
AbbVie Inc. has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Buy on 2026-04-30.What companies are similar to ABBV?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), NVS (Novartis AG), AMGN (Amgen Inc.), ABT (Abbott Laboratories). Compare ABBV side-by-side with any of them on Quantisnow.How can I track ABBV on Quantisnow?
Quantisnow aggregates AbbVie Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABBV to receive live email and push alerts on every new disclosure.